User profiles for M.G. Matera

Maria Gabriella Matera

Napoli
Verified email at unicampania.it
Cited by 15055

[HTML][HTML] ACE2: the major cell entry receptor for SARS-CoV-2

F Scialo, A Daniele, F Amato, L Pastore, MG Matera… - Lung, 2020 - Springer
Despite the unprecedented effort of the scientific community, the novel SARS-CoV-2 virus
has infected more than 46 million people worldwide, killing over one million two hundred …

Pharmacology and therapeutics of bronchodilators

M Cazzola, CP Page, L Calzetta, MG Matera - Pharmacological Reviews, 2012 - ASPET
Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical …

β2-Agonist Therapy in Lung Disease

…, CP Page, P Rogliani, MG Matera - American journal of …, 2013 - atsjournals.org
β 2 -Agonists are effective bronchodilators due primarily to their ability to relax airway
smooth muscle (ASM). They exert their effects via their binding to the active site of β 2 -…

Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis

…, AG Chuchalin, P Rogliani, MG Matera - European …, 2015 - Eur Respiratory Soc
… use of N-acetylcysteine (NAC) at 600 mg twice daily can prevent exacerbations, especially
in … (1200 mg daily) of NAC [1], double the 600 mg daily dose of NAC used in BRONCUS [3]. …

[HTML][HTML] Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?

F Perrotta, MG Matera, M Cazzola, A Bianco - Respiratory medicine, 2020 - Elsevier
SARS-CoV-2 is a novel virus of the Coronaviridiae family that represents a major global
health issue. Mechanisms implicated in virus/host cells interaction are central for cell infection …

A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD

L Calzetta, P Rogliani, MG Matera, M Cazzola - Chest, 2016 - Elsevier
Background The wide availability of long-acting muscarinic antagonist (LAMA)/long-acting
β2-agonist (LABA) fixed-dose combinations (FDCs) in the absence of head-to-head …

[HTML][HTML] The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections

…, C Page, GM Rossolini, L Pallecchi, MG Matera… - Respiratory …, 2016 - Elsevier
… This study reported a concentration-related decrease in biofilm formation (at concentrations
>0.25 mg/ml); furthermore, the inhibitory effect of 2 mg/ml of NAC on matrix formation was …

[HTML][HTML] Optimizing drug delivery in COPD: the role of inhaler devices

…, A Coppola, F Cavalli, J Ora, E Puxeddu, MG Matera… - Respiratory …, 2017 - Elsevier
Background Inhaled medication is the cornerstone of the pharmacological treatment for
patients with asthma and chronic obstructive pulmonary disease (COPD). Several inhaler …

β2‐adrenoceptor agonists: current and future direction

…, L Calzetta, MG Matera - British journal of …, 2011 - Wiley Online Library
Despite the passionate debate over the use of β 2 ‐adrenoceptor agonists in the treatment
of airway disorders, these agents are still central in the symptomatic management of asthma …

Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia

…, F Di Perna, F Calderaro, A Imperatore, MG Matera - Chest, 1998 - Elsevier
Objective There are several reports of documented adverse cardiac effects during treatment
with β-agonists. Since one should be aware that this may be a problem in patients with …